Oncolytics Biotech, Inc [NASDAQ: ONCY] slipped around -0.01 points on Thursday, while shares priced at $0.56 at the close of the session, down -1.23%.
Compared to the average trading volume of 517.49K shares, ONCY reached a trading volume of 214464 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Oncolytics Biotech, Inc [ONCY]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ONCY shares is $3.74 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ONCY stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Maxim Group have made an estimate for Oncolytics Biotech, Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on October 06, 2022. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on February 17, 2021, representing the official price target for Oncolytics Biotech, Inc stock.
The Average True Range (ATR) for Oncolytics Biotech, Inc is set at 0.05 The Price to Book ratio for the last quarter was 10.79, with the Price to Cash per share for the same quarter was set at 0.13.
How has ONCY stock performed recently?
Oncolytics Biotech, Inc [ONCY] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 12.18. With this latest performance, ONCY shares dropped by -9.59% in over the last four-week period, additionally sinking by -54.76% over the last 6 months – not to mention a drop of -48.06% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ONCY stock in for the last two-week period is set at 46.00, with the RSI for the last a single of trading hit 48.67, and the three-weeks RSI is set at 44.11 for Oncolytics Biotech, Inc [ONCY]. The present Moving Average for the last 50 days of trading for this stock 0.6442, while it was recorded at 0.5829 for the last single week of trading, and 0.8967 for the last 200 days.
Oncolytics Biotech, Inc [ONCY]: Deeper insight into the fundamentals
Oncolytics Biotech, Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.82 and a Current Ratio set at 2.82.
Earnings analysis for Oncolytics Biotech, Inc [ONCY]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ONCY. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Oncolytics Biotech, Inc go to 5.39%.
Insider trade positions for Oncolytics Biotech, Inc [ONCY]
There are presently around $1.63%, or 1.70%% of ONCY stock, in the hands of institutional investors. The top three institutional holders of ONCY stocks are: INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC with ownership of 0.2 million shares, which is approximately 0.2607%. SEEDS INVESTOR LLC, holding 0.19 million shares of the stock with an approximate value of $$0.19 million in ONCY stocks shares; and SEEDS INVESTOR LLC, currently with $$0.14 million in ONCY stock with ownership which is approximately 0.182%.
